Novo CEO pressed by Senate to cut costs of being overweight, diabetic issues medications CEO Lars Fruergaard Jørgensen explained to lawmakers the company would take into consideration new talks with insurers regarding the listing rates of Wegovy and copyright whenever they pledge to maintain the medicines on their own formularies. https://finnpgwmc.bloggactivo.com/30102288/details-fiction-and-healthcare-news